Progyny, Inc. (NASDAQ:PGNY) Given Average Rating of “Hold” by Brokerages

Progyny, Inc. (NASDAQ:PGNYGet Free Report) has been given an average recommendation of “Hold” by the thirteen ratings firms that are currently covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $25.50.

A number of brokerages recently commented on PGNY. Bank of America lowered their target price on Progyny from $22.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday. Truist Financial reiterated a “hold” rating and set a $19.00 target price (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Canaccord Genuity Group dropped their price target on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 target price on shares of Progyny in a report on Tuesday, October 1st.

Read Our Latest Report on PGNY

Insider Buying and Selling

In other Progyny news, Chairman David J. Schlanger bought 150,000 shares of the stock in a transaction dated Thursday, December 26th. The shares were acquired at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the transaction, the chairman now owns 228,269 shares in the company, valued at approximately $3,350,988.92. The trade was a 191.65 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Peter Anevski purchased 209,500 shares of Progyny stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the transaction, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. The trade was a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Progyny

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP lifted its position in Progyny by 1,900.0% in the second quarter. Quarry LP now owns 880 shares of the company’s stock valued at $25,000 after purchasing an additional 836 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Progyny during the second quarter worth $44,000. GAMMA Investing LLC raised its position in Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after acquiring an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after acquiring an additional 1,526 shares during the period. Finally, Caitlin John LLC boosted its position in shares of Progyny by 2,974.8% during the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock worth $57,000 after purchasing an additional 3,183 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

NASDAQ PGNY opened at $23.59 on Wednesday. The stock’s fifty day moving average is $17.10 and its two-hundred day moving average is $19.21. The firm has a market capitalization of $2.01 billion, a P/E ratio of 40.67, a price-to-earnings-growth ratio of 2.11 and a beta of 1.31. Progyny has a fifty-two week low of $13.39 and a fifty-two week high of $42.08.

Progyny (NASDAQ:PGNYGet Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s revenue was up 2.0% on a year-over-year basis. As a group, sell-side analysts forecast that Progyny will post 0.6 EPS for the current year.

Progyny Company Profile

(Get Free Report

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Articles

Analyst Recommendations for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.